Abstract
The environment and events that we are exposed to in utero, during birth and in early childhood influence our future physical and mental health. The underlying mechanisms that lead to these outcomes in adulthood are unclear, but long-term changes in epigenetic marks, such as DNA methylation, could act as a mediating factor or biomarker. DNA methylation data was assayed at 713,522 CpG sites from 9,537 participants of the Generation Scotland: Scottish Family Health Study, a family-based cohort with extensive data on genetic, medical, family history and lifestyle information. Methylome-wide association studies of eight early life environment phenotypes and two adult mental health phenotypes were conducted using DNA methylation data collected from adult whole blood samples. Two genes involved with different developmental pathways (PRICKLE2 and ABI1) were annotated to CpG sites associated with preterm birth (P < 1.27 × 10 −9). A further two genes important to the development of sensory pathways (SOBP and RPGRIP1) were annotated to sites associated with low birth weight (P < 4.35 × 10−8). Genes and gene-sets annotated from associated CpGs sites and methylation profile scores were then used to quantify any overlap between the early life environment and mental health traits. However, there was no evidence of any overlap after applying a correction for multiple testing. Time of year of birth was found to be associated with a significant difference in estimated lymphocyte and neutrophil counts. Early life environments influence the risk of developing mental health disorders later in life; however, this study provides no evidence that this is mediated by stable changes to the methylome detectable in peripheral blood.
Competing Interest Statement
A.M.McI. has received research support from Eli Lilly and Company, Janssen and the Sackler Trust and speaker fees from Illumina and Janssen. C.M.L is a member of the Myriad Neuroscience R&D SAB.
Funding Statement
Generation Scotland received core support from the Chief Scientist Office of the Scottish Government Health Directorates [CZD/16/6] and the Scottish Funding Council [HR03006] and is currently supported by the Wellcome Trust [216767/Z/19/Z]. Genotyping of the GS:SFHS samples was carried out by the Genetics Core Laboratory at the Edinburgh Clinical Research Facility, University of Edinburgh, Scotland and was funded by the Medical Research Council UK and the Wellcome Trust (Wellcome Trust Strategic Award "STratifying Resilience and Depression Longitudinally" (STRADL) Reference 104036/Z/14/Z). We are grateful to all the families who took part, the general practitioners and the Scottish School of Primary Care for their help in recruiting them, and the whole Generation Scotland team, including interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists, healthcare assistants and nurses. Ethics approval for the study was given by the NHS Tayside committee on research ethics (reference 05/S1401/8). LBC1921 funding has been received from the UK's Biotechnology and Biological Sciences Research Council (BBSRC) (15/SAG09977, wave 1), a Royal Society-Wolfson Research Merit Award to IJD (wave 2), the Chief Scientist Office (CSO) of the Scottish Government's Health Directorates (CZG/3/2/79, post-wave 1 questionnaire study; CZB/4/505, wave 3; ETM/55, wave 4), and the UK's Medical Research Council (MRC) Centenary Early Career Award to Dr Tom Booth (wave 5). Funding for LBC1936 has been received from Research Into Ageing (Programme grant 251; wave 1), and Age UK (Disconnected Mind Programme grant) and the UK's Medical Research Council (G0701120, wave 2; G1001245, wave 3; MR/M013111/1, wave 4). The Alzheimer Scotland Dementia Research Centre funded LBC1936 dementia ascertainment. BBSRC funded whole-genome sequencing of both cohorts. Wellcome, the University of Edinburgh, the University of Queensland, and Age UK funded DNA methylation analysis in both cohorts. D.M.H is supported by a Sir Henry Wellcome Postdoctoral Fellowship (Reference 213674/Z/18/Z) and a 2018 NARSAD Young Investigator Grant from the Brain & Behavior Research Foundation (Ref: 27404). A.M.McI is supported by Wellcome Trust (104036/Z/14/Z and 216767/Z/19/Z) and UKRI MRC funding (MC PC 17209 and MR/S035818/1). C.A is supported by the Medical Research Council (MRC) UK (grants MC_PC_U127592696 and MC_PC_U127561128). I.J.D. was supported by the Centre for Cognitive Ageing and Cognitive Epidemiology, which was funded by the Medical Research Council and the Biotechnology and Biological Sciences Research Council (MR/K026992/1). R.E.M is supported by Alzheimer's Research UK major project grant ARUK-PG2017B-10. N.R.W. acknowledges NMHRC grants 1078901 and 1087889. L.A is the Mental Health Leadership Fellow for the ESRC. C.M.L acknowledges MRC grant MR/N015746/1. This investigation represents independent research part-funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval for Generation Scotland was given by the NHS Tayside committee on research ethics (reference 05/S1401/8).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Methylome-wide summary statistics calculated from MWAS 1 and MWAS 2 for each of the assessed phenotypes will be made publicly available following publication of the peer-reviewed manuscript
